Curated News
By: NewsRamp Editorial Staff
April 25, 2025
Soligenix's HyBryte Shows Promising Results in Treating Rare Skin Cancer
TLDR
- Soligenix's lead candidate, HyBryte, achieved a 75% response rate in a trial for CTCL, offering a competitive edge in treating rare diseases.
- HyBryte is a first-in-class photodynamic therapy using safe visible light, with Orphan Drug and Fast Track designations, positioning it for potential commercialization.
- HyBryte's success in treating CTCL showcases its potential to make a positive impact on patients' lives, offering hope for those with rare diseases.
- HyBryte's innovative approach as a light-activated therapy for CTCL provides an educational insight into cutting-edge treatments for rare diseases.
Impact - Why it Matters
This news matters as it highlights the potential breakthrough in treating cutaneous T-cell lymphoma, a rare and challenging form of skin cancer. The success of HyBryte, with its high response rate in clinical trials, offers hope to patients and showcases the innovative approach of Soligenix in addressing unmet medical needs.
Summary
Soligenix (NASDAQ: SNGX), a late-stage biopharmaceutical company, is highlighted in a Benzinga video showcasing the success of its lead candidate, HyBryte, in treating cutaneous T-cell lymphoma. The therapy achieved a 75% response rate in a recent trial, positioning it as a potential first-in-class therapy for this rare form of skin cancer.
HyBryte, a photodynamic therapy activated by visible light, has received Orphan Drug and Fast Track designations. Soligenix plans to continue regulatory discussions to advance the therapy towards commercialization.
Source Statement
This curated news summary relied on this press release disributed by InvestorBrandNetwork (IBN). Read the source press release here, Soligenix's HyBryte Shows Promising Results in Treating Rare Skin Cancer
